Global Health Equity

Chewable formulation of mebendazole will address an unmet need in treating intestinal worms in young children

First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization. An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected countries and to prevent future outbreaks. Partners involved in the clinical program for the Ebola vaccine regimen include the Janssen Pharmaceutical Companies of Johnson & Johnson, the London School of Hygiene & Tropical Medicine, the University of Oxford, Inserm, Bavarian Nordic and Europe’s Innovative Medicines Initiative.

Prime-boost vaccine regimen in development at the Janssen Pharmaceutical Companies currently in Phase I and II clinical studies in Europe, U.S. and Africa

Consortia funded through the IMI Ebola+ Programme Supported by the European Commission Brings together London School of Hygiene and Tropical Medicine, Inserm, University of Oxford, Le Centre Muraz, Bavarian Nordic A/S, Vibalogics, the Grameen Foundation and World Vision of Ireland with Janssen Pharmaceutical Companies to help accelerate Ad26 – MVA Ebola vaccine development and patient education

Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide